The regulatory role of MicroRNAs in EMT and cancer

Journal of Oncology

Volumn 2015, Issue , 2015, Pages

  Zaravinos, Apostolos ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBRONECTIN; FRIZZLED PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN LINKED KINASE; MICRORNA; MICRORNA 101; MICRORNA 141; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 429; NERVE CELL ADHESION MOLECULE; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR; SMAD2 PROTEIN; SMAD4 PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE RECEPTOR; UVOMORULIN; VIMENTIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACTIN FILAMENT; APOPTOSIS; BREAST CANCER; CANCER STEM CELL; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL POLARITY; CELL PROLIFERATION; CELL STRUCTURE; CYTOARCHITECTURE; CYTOPLASM; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEEDBACK SYSTEM; GENE EXPRESSION; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; METASTASIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; TUMOR MICROENVIRONMENT; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 84926676589     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2015/865816     Document Type: Review

References (162)

1. J. L. Duband, F. Monier, M. Delannet, and D. Newgreen, "Epithelium-mesenchyme transition during neural crest development," Acta Anatomica, vol. 154, no. 1, pp. 63-78, 1995.
2. D. L. Bolender and R. R. Markwald, "Epithelial-mesenchymal transformation in chick atrioventricular cushion morphogenesis," Scanning Electron Microscopy, vol. 3, pp. 313-321, 1979.
3. C.M. Griffith and E. D.Hay, "Epithelial-mesenchymal transformation during palatal fusion: carboxyfluorescein traces cells at light and electron microscopic levels," Development, vol. 116, no. 4, pp. 1087-1099, 1992.
4. M. Yilmaz and G. Christofori, "EMT, the cytoskeleton, and cancer cell invasion," Cancer and Metastasis Reviews, vol. 28,no. 1-2, pp. 15-33, 2009.
5. R. Kalluri and R. A. Weinberg, "The basics of epithelialmesenchymal transition," Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420-1428, 2009.
6. U. Soomets, M. Hällbrink, and U. Langel, "Antisense properties of peptide nucleic acids," Frontiers in Bioscience, vol. 4, pp. D782-D786, 1999.
7. J. P. Thiery and J. P. Sleeman, "Complex networks orchestrate epithelial-mesenchymal transitions," Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131-142, 2006.
8. J. P. Their, "Epithelial-mesenchymal transitions in tumor progression," Nature Reviews Cancer, vol. 2, no. 6, pp. 442-454, 2002.
9. S. M. Hansen, V. Berezin, and E. Bock, "Signaling mechanisms of neurite outgrowth induced by the cell adhesion molecules NCAM and N-Cadherin," Cellular and Molecular Life Sciences, vol. 65, no. 23, pp. 3809-3821, 2008.
10. G. Ouyang, Z.Wang, X. Fang, J. Liu, and C. J. Yang, "Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells," Cellular and Molecular Life Sciences, vol. 67, no. 15, pp. 2605-2618, 2010.
11. J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, "Epithelial-mesenchymal transitions in development and disease," Cell, vol. 139, no. 5, pp. 871-890, 2009.
12. S. Spaderna, O. Schmalhofer, M. Wahlbuhl et al., "The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer," Cancer Research, vol. 68, no. 2, pp. 537-544, 2008.
13. L. D. Wood, D. W. Parsons, S. Jones et al., "The genomic landscapes of human breast and colorectal cancers," Science, vol. 318, pp. 1108-1113, 2007.
14. S. Jones, X. Zhang, D. W. Parsons et al., "Core signaling pathways in human pancreatic cancers revealed by global genomic analyses," Science, vol. 321, no. 5897, pp. 1801-1806, 2008.
15. S. Lamouille, J. Xu, and R. Derynck, "Molecular mechanisms of epithelial-mesenchymal transition," Nature Reviews Molecular Cell Biology, vol. 15, no. 3, pp. 178-196, 2014.
16. J. Fuxe, T. Vincent, and A. G. de Herreros, "Transcriptional crosstalk between TGFβ and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes," Cell Cycle, vol. 9, no. 12, pp. 2363-2374, 2010.
17. J. Zavadil and E. P. Böttinger, "TGF-β and epithelial-tomesenchymal transitions," Oncogene, vol. 24, no. 37, pp. 5764-5774, 2005.
18. J. Gotzmann, M. Mikula, A. Eger et al., "Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis," Mutation Research-Reviews in Mutation Research, vol. 566, no. 1, pp. 9-20, 2004.
19. Y.Wang and B. P. Zhou, "Epithelial-mesenchymal transition in breast cancer progression and metastasis," Chinese Journal of Cancer, vol. 30, no. 9, pp. 603-611, 2011.
20. M. Garg, "Epithelial-mesenchymal transition-activating transcription factors-multifunctional regulators in cancer," World Journal of StemCells, vol. 5, no. 4, pp. 188-195, 2013.
21. B. T. MacDonald, K. Tamai, and X. He, "Wnt/β-catenin signaling: components, mechanisms, and diseases," Developmental Cell, vol. 17, no. 1, pp. 9-26, 2009.
22. T. P. Rao and M. Kühl, "An updated overview on wnt signaling pathways: a prelude formore," Circulation Research, vol. 106, no. 12, pp. 1798-1806, 2010.
23. F. H. Sarkar, Y. Li, Z. Wang, and D. Kong, "The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer," Cancer and Metastasis Reviews, vol. 29,no. 3, pp. 383-394, 2010.
24. L.Miele, "Notch signaling," Clinical Cancer Research, vol. 12,no. 4, pp. 1074-1079, 2006.
25. Z. Wang, Y. Li, D. Kong, and F. H. Sarkar, "The role of notch signaling pathway in Epithelial-Mesenchymal Transition (EMT) during development and tumor aggressiveness," Current Drug Targets, vol. 11, no. 6, pp. 745-751, 2010.
26. S. J. Bray, "Notch signalling: a simple pathway becomes complex," Nature Reviews Molecular Cell Biology, vol. 7, no. 9, pp. 678-689, 2006.
27. K. G. Leong, K. Niessen, I. Kulic et al., "Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin," Journal of Experimental Medicine, vol. 204, no. 12, pp. 2935-2948, 2007.
28. G. M. Collu and K. Brennan, "Cooperation between Wnt and Notch signalling in human breast cancer," Breast Cancer Research, vol. 9, no. 3, article 105, 2007.
29. M. J. Wheelock and K. R. Johnson, "Cadherin-mediated cellular signaling," Current Opinion in Cell Biology, vol. 15, no. 5, pp. 509-514, 2003.
30. M. Zeisberg and E. G. Neilson, "Biomarkers for epithelialmesenchymal transitions,"The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1429-1437, 2009.
31. Q. Wang, Y. Wang, Y. Zhang, and W. Xiao, "The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease," Respiratory Research, vol. 14, no. 1, article 67, 2013.
32. N.Chandrasekar, S. Mohanam, M. Gujrati,W. C. Olivero, D. H. Dinh, and J. S. Rao, "Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells," Oncogene, vol. 22, no. 3, pp. 392-400, 2003.
33. M. Jo, R. D. Lester, V.Montel, B. Eastman, S. Takimoto, and S. L. Gonias, "Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling," The Journal of Biological Chemistry, vol. 284, no. 34, pp. 22825-22833, 2009.
34. R. D. Lester, M. Jo, V. Montel, S. Takimoto, and S. L. Gonias, "uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells," Journal of Cell Biology, vol. 178, no. 3, pp. 425-436, 2007.
35. L. Larue and A. Bellacosa, "Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways," Oncogene, vol. 24, no. 50, pp. 7443-7454, 2005.
36. A. Kozomara and S. Griffiths-Jones, "MiRBase: integrating microRNA annotation and deep-sequencing data," Nucleic Acids Research, vol. 39, no. 1, pp. D152-D157, 2011.
37. J. Krol, I. Loedige, and W. Filipowicz, "The widespread regulation of microRNA biogenesis, function and decay," Nature Reviews Genetics, vol. 11, no. 9, pp. 597-610, 2010.
38. T. Dalmay, "Mechanism of miRNA-mediated repression of mRNAtranslation," Essays in Biochemistry, vol. 54,no. 1, pp. 29-38, 2013.
39. A. Zaravinos, G. I. Lambrou, N. Mourmouras et al., "New miRNA profiles accurately distinguish renal cell carcinomas and upper tract urothelial carcinomas fromthe normal kidney," PLoS ONE, vol. 9, no. 3,Article ID e91646, 2014.
40. J. Radojicic,A. Zaravinos, T.Vrekoussis, M.Kafousi,D. A. Spandidos, and E. N. Stathopoulos, "MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer," Cell Cycle, vol. 10, no. 3, pp. 507-517, 2011.
41. I. Chaveles, A. Zaravinos, I. G. Habeos et al., "MicroRNA profiling in murine liver after partial hepatectomy," International Journal of Molecular Medicine, vol. 29, no. 5, pp. 747-755, 2012.
42. D. V. Chartoumpekis, A. Zaravinos, P. G. Ziros et al., "Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice," PLoS ONE, vol. 7, no. 4, Article ID e34872, 2012.
43. A. Zaravinos, J. Radojicic, G. I. Lambrou et al., "Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer," Journal of Urology, vol. 188, no. 2, pp. 615-623, 2012.
44. T. M. Rana, "Illuminating the silence: understanding the structure and function of smallRNAs," Nature ReviewsMolecular Cell Biology, vol. 8, no. 1, pp. 23-36, 2007.
45. B. Zhang, Q.Wang, and X. Pan, "MicroRNAs and their regulatory roles in animals and plants," Journal of Cellular Physiology, vol. 210, no. 2, pp. 279-289, 2007.
46. W. Filipowicz, L. Jaskiewicz, F. A. Kolb, and R. S. Pillai, "Posttranscriptional gene silencing by siRNAs and miRNAs," Current Opinion in Structural Biology, vol. 15, no. 3, pp. 331-341, 2005.
47. J. Hausser, A. P. Syed, B. Bilen, and M. Zavolan, "Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation," Genome Research, vol. 23, no. 4, pp. 604-615, 2013.
48. B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, "microRNAs as oncogenes and tumor suppressors," Developmental Biology, vol. 302, no. 1, pp. 1-12, 2007.
49. E. M. C. Ohlsson Teague, C. G. Print, and M. L. Hull, "The role of microRNAs in endometriosis and associated reproductive conditions,"HumanReproductionUpdate, vol. 16,no. 2, pp. 142-165, 2009.
50. M. Koutsaki, D. A. Spandidos, and A. Zaravinos, "Epithelialmesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics," Cancer Letters, vol. 351, pp. 173-181, 2014.
51. X. Feng, Z.Wang, R. Fillmore, and Y. Xi, "MiR-200, a new star miRNA in human cancer," Cancer Letters, vol. 344, no. 2, pp. 166-173, 2014.
52. A. Díaz-López, G. Moreno-Bueno, and A. Cano, "Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives," Cancer Management and Research, vol. 6, no. 1, pp. 205-216, 2014.
53. L. Adam, M. Zhong, W. Choi et al., "miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy," Clinical Cancer Research, vol. 15,no. 16,pp. 5060-5072, 2009.
54. V. P. Tryndyak, F. A. Beland, and I. P. Pogribny, "E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drugresistant phenotypes in human breast cancer cells," International Journal of Cancer, vol. 126, no. 11, pp. 2575-2583, 2010.
55. E. D. Wiklund, J. B. Bramsen, T. Hulf et al., "Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer," International Journal of Cancer, vol. 128, no. 6, pp. 1327-1334, 2011.
56. D. M. Dykxhoorn, Y. Wu, H. Xie et al., "miR-200 enhances mouse breast cancer cell colonization to form distant metastases," PLoS ONE, vol. 4, no. 9,Article ID e7181, 2009.
57. I. Elson-Schwab, A. Lorentzen, and C. J.Marshall, "MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion," PLoS ONE, vol. 5, no. 10, Article ID e13176, 2010.
58. X. Hu, D. M. Macdonald, P. C. Huettner et al., "A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer," Gynecologic Oncology, vol. 114, no. 3, pp. 457-464, 2009.
59. S. Ali, A. Ahmad, S. Banerjee et al., "Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF," Cancer Research, vol. 70, no. 9, pp. 3606-3617, 2010.
60. Y. Li, T. G. Vandenboom II, D. Kong et al., "Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells," Cancer Research, vol. 69, no. 16, pp. 6704-6712, 2009.
61. D. Kong, Y. Li, Z. Wang et al., "miR-200 regulates PDGFD-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells," Stem Cells, vol. 27, no. 8, pp. 1712-1721, 2009.
62. A. Shinozaki, T. Sakatani, T. Ushiku et al., "Downregulation of microRNA-200 in EBV-associated gastric carcinoma," Cancer Research, vol. 70, no. 11, pp. 4719-4727, 2010.
63. D. L. Gibbons, W. Lin, C. J. Creighton et al., "Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression," Genes and Development, vol. 23, no. 18, pp. 2140-2151, 2009.
64. P. A. Gregory, A. G. Bert, E. L. Paterson et al., "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1," Nature Cell Biology, vol. 10, no. 5, pp. 593-601, 2008.
65. S.-M. Park, A. B. Gaur, E. Lengyel, and M. E. Peter, "ThemiR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2," Genes &Development, vol. 22, no. 7, pp. 894-907, 2008.
66. M. Pacurari, J. B. Addison, N. Bondalapati et al., "The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells," International Journal of Oncology, vol. 43, no. 2, pp. 548-560, 2013.
67. M. J. Schliekelman, D. L. Gibbons, V. M. Faca et al., "Targets of the tumor suppressor miR-200 in regulation of the epithelialmesenchymal transition in cancer," Cancer Research, vol. 71, no. 24, pp. 7670-7682, 2011.
68. P. A. Gregory, C. P. Bracken, E. Smith et al., "An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition," Molecular Biology of the Cell, vol. 22, no. 10, pp. 1686-1698, 2011.
69. C. Vandewalle, F. Van Roy, and G. Berx, "The role of the ZEB family of transcription factors in development and disease," Cellular and Molecular Life Sciences, vol. 66, no. 5, pp. 773-787, 2009.
70. L. Hill, G. Browne, and E. Tulchinsky, "ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer," International Journal ofCancer, vol. 132, no.4,pp. 745-754, 2012.
71. G. J. Hurteau, J.A. Carlson, S.D. Spivack, and G. J. Brock, "Overexpression of the MicroRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin," Cancer Research, vol. 67, no. 17, pp. 7972-7976, 2007.
72. M. Korpal, E. S. Lee, G. Hu, and Y. Kang, "The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2," The Journal of Biological Chemistry, vol. 283, no. 22, pp. 14910-14914, 2008.
73. U. Burk, J. Schubert, U. Wellner et al., "A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells," EMBO Reports, vol. 9, no. 6, pp. 582-589, 2008.
74. C. P. Bracken, P. A. Gregory, N. Kolesnikoff et al., "A doublenegative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition," Cancer Research, vol. 68, no. 19, pp. 7846-7854, 2008.
75. S. Brabletz and T. Brabletz, "The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?" EMBO Reports, vol. 11, no. 9, pp. 670-677, 2010.
76. J. Kurashige, H. Kamohara, M. Watanabe et al., "MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma," Annals of Surgical Oncology, vol. 19, supplement 3, pp. S656-S664, 2012.
77. N. Cong, P. Du, A. Zhang et al., "Downregulated microRNA-200a promotes EMT and tumor growth through the Wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma," Oncology Reports, vol. 29, no. 4, pp. 1579-1587, 2013.
78. S. Grünert, M. Jechlinger, and H. Beug, "Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis," Nature Reviews Molecular Cell Biology, vol. 4, no. 8, pp. 657-665, 2003.
79. M. Jechlinger, A. Sommer,R.Moriggl et al., "Autocrine PDGFR signaling promotes mammary cancer metastasis," Journal of Clinical Investigation, vol. 116, no. 6, pp. 1561-1570, 2006.
80. J.Gotzmann, A.N. Fischer, M. Zojer et al., "Acrucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes," Oncogene, vol. 25, no. 22, pp. 3170-3185, 2006.
81. K. Lehmann, E. Janda, C. E. Pierreux et al., "Raf induces TGFβ production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells," Genes and Development, vol. 14, no. 20, pp. 2610-2622, 2000.
82. A. Eger, A. Stockinger, B. Schaffhauser, H. Beug, and R. Foisner, "Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of β-catenin and upregulation of β-catenin/lymphoid enhancer binding factor-1 transcriptional activity," Journal of Cell Biology, vol. 148, no. 1, pp. 173-187, 2000.
83. J.Lu, H. Guo,W. Treekitkarnmongkol et al., "14-3-3ζ cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition," Cancer Cell, vol. 16, no. 3, pp. 195-207, 2009.
84. J. Braun, C. Hoang-Vu, H. Dralle, and S. Hüttelmaier, "Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas," Oncogene, vol. 29, no. 29, pp. 4237-4244, 2010.
85. J. L. Carstens, S. Lovisa, and R. Kalluri, "Microenvironmentdependent cues trigger miRNA-regulated feedback loop to facilitate the EMT/MET switch," Journal of Clinical Investigation, vol. 124, no. 4, pp. 1458-1460, 2014.
86. G. Berx, E. Raspé, G. Christofori, J. P. Thiery, and J. P. Sleeman, "Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer," Clinical&ExperimentalMetastasis, vol. 24, no. 8, pp. 587-597, 2007.
87. L. F. Sempere, M. Christensen, A. Silahtaroglu et al., "Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer," Cancer Research, vol. 67, no. 24, pp. 11612-11620, 2007.
88. P. A. Gregory, C. P. Bracken, A. G. Bert, and G. J. Goodall, "MicroRNAs as regulators of epithelial-mesenchymal transition," Cell Cycle, vol. 7, no. 20, pp. 3112-3118, 2008.
89. M. Kato, J. Zhang, M. Wang et al., "MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors," Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 104, no. 9, pp. 3432-3437, 2007.
90. P. Ru, R. Steele, P. Newhall, N. J. Phillips, K. Toth, and R. B. Ray, "miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling,"Molecular CancerTherapeutics, vol. 11, no. 5, pp. 1166-1173, 2012.
91. J. Zhang, H. Zhang, J. Liu et al., "MiR-30 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1," Biochemical and Biophysical Research Communications, vol. 417, no. 3, pp. 1100-1105, 2012.
92. R. Kumarswamy, G. Mudduluru, P. Ceppi et al., "MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer," International Journal of Cancer, vol. 130, no. 9, pp. 2044-2053, 2012.
93. J.P.Zhang,C.Zeng, L. Xu, J.Gong, J.H. Fang, and S.M. Zhuang, "MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling," Oncogene, vol. 33, pp. 4069-4076, 2014.
94. H. Siemens, R. Jackstadt, S. Hünten et al., "miR-34 and SNAIL form a double-negative feedback loop to regulate epithelialmesenchymal transitions," Cell Cycle, vol. 10, no. 24, pp. 4256-4271, 2011.
95. M. Moes, A. Le Béchec, I. Crespo et al., "A novel network integrating a mirna-203/snai1 feedback loop which regulates epithelial to mesenchymal transition," PLoS ONE, vol. 7, no. 4, Article ID e35440, 2012.
96. L. Ma, J. Teruya-Feldstein, and R. A. Weinberg, "Tumour invasion and metastasis initiated by microRNA-10b in breast cancer," Nature, vol. 449, no. 7163, pp. 682-688, 2007.
97. A. E. G. Lenferink, C. Cantin, A. Nantel et al., "Transcriptome profiling of a TGF-β-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies," Oncogene, vol. 29, no. 6, pp. 831-844, 2010.
98. G. Turcatel, N. Rubin, A. El-Hashash, and D. Warburton, "Mir-99a and mir-99b modulate TGF-β induced epithelial to mesenchymal plasticity in normal murine mammary gland cells," PLoS ONE, vol. 7, no. 1,Article ID e31032, 2012.
99. W. Kong, H. Yang, L. He et al., "MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA," Molecular and Cellular Biology, vol. 28, no. 22, pp. 6773-6784, 2008.
100. C. A. Gebeshuber, K. Zatloukal, and J. Martinez, "miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis," EMBO Reports, vol. 10, no. 4, pp. 400-405, 2009.
101. C. L. Cottonham, S. Kaneko, and L. Xu, "miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells," Journal of Biological Chemistry, vol. 285, no. 46, pp. 35293-35302, 2010.
102. G. Eades, Y. Yao, M. Yang, Y. Zhang, S. Chumsri, and Q. Zhou, "miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells," Journal of Biological Chemistry, vol. 286, no. 29, pp. 25992-26002, 2011.
103. P. S. Eis, W. Tam, L. Sun et al., "Accumulation of miR-155 and BIC RNA in human B cell lymphomas," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 10, pp. 3627-3632, 2005.
104. O. Slaby, M. Svoboda, P. Fabian et al., "Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer," Oncology, vol. 72,no. 5-6, pp. 397-402, 2008.
105. S. Valastyan, A. Chang, N. Benaich, F. Reinhardt, and R. A. Weinberg, "Activation of miR-31 function in already-established metastases elicits metastatic regression," Genes and Development, vol. 25, no. 6, pp. 646-659, 2011.
106. L. Ma, J. Young, H. Prabhala et al., "MiR-9, a MYC/MYCNactivated microRNA, regulates E-cadherin and cancer metastasis," Nature Cell Biology, vol. 12, no. 3, pp. 247-256, 2010.
107. F. Ceteci, S. Ceteci, C. Karreman et al., "Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer," Cancer Cell, vol. 12, no. 2, pp. 145-159, 2007.
108. Z. Meng, X. Fu, X. Chen et al., "miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice," Hepatology, vol. 52, no. 6, pp. 2148-2157, 2010.
109. L.-Y. Zhang, M. Liu, X. Li, and H. Tang, "MiR-490-3pmodulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulumgolgi intermediate compartment protein 3 (ERGIC3)," Journal of Biological Chemistry, vol. 288, no. 6, pp. 4035-4047, 2013.
110. M.Nishikawa, Y. Kira, Y. Yabunaka, and M. Inoue, "Identification and characterization of endoplasmic reticulum-associated protein, ERp43," Gene, vol. 386, no. 1-2, pp. 42-51, 2007.
111. F. E. Wang, C. Zhang, A. Maminishkis et al., "MicroRNA-204/211 alters epithelial physiology," FASEB Journal, vol. 24, no. 5, pp. 1552-1571, 2010.
112. A. Barrios, R. J. Poole, L. Durbin, C. Brennan, N. Holder, and S. W. Wilson, "Eph/Ephrin signaling regulates the mesenchymalto-epithelial transition of the paraxial mesodermduring somite morphogenesis," Current Biology, vol. 13, no. 18, pp. 1571-1582, 2003.
113. J. Fukai, H. Yokote, R. Yamanaka, T. Arao, K. Nishio, and T. Itakura, "EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line,"Molecular CancerTherapeutics, vol. 7, no. 9, pp. 2768-2778, 2008.
114. Y. Yan, Y.-C. Luo, H.-Y. Wan et al., "MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells," Hepatology, vol. 57, no. 2, pp. 667-677, 2013.
115. S. Stinson, M. R. Lackner, A. T. Adai et al., "TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer," Science Signaling, vol. 4, no. 177, article ra41, 2011.
116. Z. Gai, G. Zhou, S. Itoh et al., "Trps1 functions downstream of Bmp7 in kidney development," Journal of the American Society of Nephrology, vol. 20, no. 11, pp. 2403-2411, 2009.
117. M. Y. Shah and G. A. Calin, "MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer," Genome Medicine, vol. 3, no. 8, article 56, 2011.
118. I.K. Guttilla, K.N. Phoenix, X. Hong, J.S. Tirnauer, K. P. Claffey, and B. A. White, "Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs," Breast Cancer Research and Treatment, vol. 132, no. 1, pp. 75-85, 2012.
119. U. Koch and F. Radtke, "Notch and cancer: a double-edged sword," Cellular and Molecular Life Sciences, vol. 64, no. 21, pp. 2746-2762, 2007.
120. L. Jiang, X. Liu, A. Kolokythas et al., "Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma," International Journal of Cancer, vol. 127, no. 3, pp. 505-512, 2010.
121. X. Liu, C. Wang, Z. Chen et al., "MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines," Biochemical Journal, vol. 440, no. 1, pp. 23-31, 2011.
122. Y. Konno, P. Dong, Y. Xiong et al., "MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells," Oncotarget, vol. 5, pp. 6049-6062, 2014.
123. Z. Wang, Y. Li, D. Kong et al., "Acquisition of epithelialmesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway," Cancer Research, vol. 69, no. 6, pp. 2400-2407, 2009.
124. S. Brabletz, K. Bajdak, S. Meidhof et al., "The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells," The EMBO Journal, vol. 30, no. 4, pp. 770-782, 2011.
125. D. M. Vallejo, E. Caparros, and M. Dominguez, "Targeting Notch signalling by the conserved miR-8/200 microRNAfamily in development and cancer cells,"TheEMBOJournal, vol. 30,no. 4, pp. 756-769, 2011.
126. S. Spaderna,O. Schmalhofer, F. Hlubek et al., "Atransient,EMTlinked loss of basement membranes indicates metastasis and poor survival in colorectal cancer,"Gastroenterology, vol. 131, no. 3, pp. 830-840, 2006.
127. E. Sánchez-Tilló, O. de Barrios, L. Siles, M. Cuatrecasas, A. Castells, and A. Postigo, "β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 48, pp. 19204-19209, 2011.
128. Y. Shi and J. Massagué, "Mechanisms of TGF-β signaling from cell membrane to the nucleus," Cell, vol. 113, no. 6, pp. 685-700, 2003.
129. H. Hermeking, "p53 enters the microRNA world," Cancer Cell, vol. 12, no. 5, pp. 414-418, 2007.
130. N. S. Chari, N. L. Pinaire, L. Thorpe, L. J. Medeiros, M. J. Routbort, and T. J. McDonnell, "The p53 tumor suppressor network in cancer and the therapeuticmodulation of cell death," Apoptosis, vol. 14, no. 4, pp. 336-347, 2009.
131. B. C. Lewis, D. S. Klimstra, N. D. Socci, S. Xu, J. A. Koutcher, and H. E. Varmus, "The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma," Molecular and Cellular Biology, vol. 25, no. 4, pp. 1228-1237, 2005.
132. Y.-W. Chen, D. S. Klimstra, M. E. Mongeau, J. L. Tatem, V. Boyartchuk, and B. C. Lewis, "Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells," Cancer Research, vol. 67, no. 16, pp. 7589-7596, 2007.
133. J. E.Hansen, L. K. Fischer, G. Chan et al., "Antibody-mediated p53 protein therapy prevents liver metastasis in vivo," Cancer Research, vol. 67, no. 4, pp. 1769-1774, 2007.
134. G. Fontemaggi, A. Gurtner, S. Strano et al., "The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation,"Molecular and Cellular Biology, vol. 21, no. 24, pp. 8461-8470, 2001.
135. T. Kim, A. Veronese, F. Pichiorri et al., "p53 regulates epithelialmesenchymal transition through microRNAs targeting ZEB1 and ZEB2," Journal of Experimental Medicine, vol. 208, no. 5, pp. 875-883, 2011.
136. C.-J. Chang, C.-H. Chao,W. Xia et al., "p53 regulates epithelialmesenchymal transition and stem cell properties throughmodulating miRNAs," Nature Cell Biology, vol. 13, no. 3, pp. 317-323, 2011.
137. E. C. Knouf, K. Garg, J. D. Arroyo et al., "An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription," Nucleic Acids Research, vol. 40, no. 2, pp. 499-510, 2012.
138. M. F. Clarke, J. E. Dick, P. B. Dirks et al., "Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells," Cancer Research, vol. 66, no. 19, pp. 9339-9344, 2006.
139. R. Chhabra and N. Saini, "MicroRNAs in cancer stem cells: current status and future directions," Tumor Biology, vol. 35, no. 9, pp. 8395-8405, 2014.
140. S. A. Mani, W. Guo, M.-J. Liao et al., "The epithelialmesenchymal transition generates cells with properties of stem cells," Cell, vol. 133, no. 4, pp. 704-715, 2008.
141. A.-P. Morel, M. Lièvre, C. Thomas, G. Hinkal, S. Ansieau, and A. Puisieux, "Generation of breast cancer stem cells through epithelial-mesenchymal transition," PLoS ONE, vol. 3, no. 8, Article ID e2888, 2008.
142. B. T. Hennessy, A. M. Gonzalez-Angulo, K. Stemke-Hale et al., "Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics," Cancer Research, vol. 69, no. 10, pp. 4116-4124, 2009.
143. B. Aktas, M. Tewes, T. Fehm, S. Hauch, R. Kimmig, and S. Kasimir-Bauer, "Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients," Breast Cancer Research, vol. 11, no. 4, article R46, 2009.
144. B. G. Hollier, K. Evans, and S. A. Mani, "The epithelial-tomesenchymal transition and cancer stem cells: a coalition against cancer therapies," Journal of Mammary Gland Biology and Neoplasia, vol. 14, no. 1, pp. 29-43, 2009.
145. M. Santisteban, J. M. Reiman, M. K. Asiedu et al., "Immuneinduced epithelial to mesenchymal transition in vivo generates breast cancer stem cells," Cancer Research, vol. 69, no. 7, pp. 2887-2895, 2009.
146. T. Blick, H. Hugo, E. Widodo et al., "Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44HI/CD24lO/-stem cell phenotype in human breast cancer," Journal of Mammary Gland Biology and Neoplasia, vol. 15, no. 2, pp. 235-252, 2010.
147. D. Kong, S. Banerjee, A. Ahmad et al., "Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells," PLoS ONE, vol. 5, no. 8, Article ID e12445, 2010.
148. J. Zavadil, "A spotlight on regulatory networks connecting EMT and cancer stem cells," Cell Cycle, vol. 9, no. 15, p. 2927, 2010.
149. A. Martin and A. Cano, "Tumorigenesis: twist1 links EMT to self-renewal," Nature Cell Biology, vol. 12, no. 10, pp. 924-925, 2010.
150. M.-H. Yang,D. S.-S.Hsu, H.-W.Wang et al., "Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition," Nature Cell Biology, vol. 12, no. 10, pp. 982-992, 2010.
151. G. J. Klarmann, E. M. Hurt, L. A. Mathews et al., "Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature," Clinical and Experimental Metastasis, vol. 26, no. 5, pp. 433-446, 2009.
152. D. J. Mulholland, N. Kobayashi, M. Ruscetti et al., "Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated fromprostate cancer stem/progenitor cells," Cancer Research, vol. 72, no. 7, pp. 1878-1889, 2012.
153. J. Lopez, A. Poitevin, V.Mendoza-Martinez, C. Perez-Plasencia, and A. Garcia-Carranca, "Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance," BMC Cancer, vol. 12, article 48, 2012.
154. R. Garzon, G. Marcucci, and C. M. Croce, "Targeting microRNAs in cancer: rationale, strategies and challenges," Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 775-789, 2010.
155. A. Bouchie, "First microRNA mimic enters clinic," Nature Biotechnology, vol. 31, no. 7, article 577, 2013.
156. F.Xiao, Y. Bai, Z. Chen et al., "Downregulation ofHOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100," European Journal of Cancer, vol. 50, no. 8, pp. 1541-1554, 2014.
157. M. X. Liu, M. K. Y. Siu, S. S. Liu, J. W. P. Yam, H. Y. S. Ngan, and D. W. Chan, "Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer," Oncotarget, vol. 5, no. 4, pp. 944-958, 2014.
158. H. L. A. Janssen, H. W. Reesink, E. J. Lawitz et al., "Treatment of HCV infection by targeting microRNA," The New England Journal of Medicine, vol. 368, no. 18, pp. 1685-1694, 2013.
159. L. F. R. Gebert, M. A. E. Rebhan, S. E.M. Crivelli, R. Denzler, M. Stoffel, and J. Hall, "Miravirsen (SPC3649) can inhibit the biogenesis of miR-122," Nucleic Acids Research, vol. 42, no. 1, pp. 609-621, 2014.
160. J. F.Wiggins, L. Ruffino,K.Kelnar et al., "Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34," Cancer Research, vol. 70, no. 14, pp. 5923-5930, 2010.
161. A. G. Bader, "MiR-34-a microRNA replacement therapy is headed to the clinic," Frontiers in Genetics, vol. 3, article 120, 2012.
162. C. L. Daige, J. F. Wiggins, L. Priddy et al., "Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer," Molecular Cancer Therapeutics, vol. 13, no. 10, pp. 2352-2360, 2014.